Condition
Gastric (Stomach) Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownRiluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot TrialNCT07447050 · 2025-12-23
RECRUITINGAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsNCT07371663 · 2025-12-03
RECRUITINGClonal Hematopoiesis Chemotherapy and Radiation Effects StudyNCT07675967 · 2025-04-04
RECRUITINGADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)NCT04044859 · 2019-08-20
ACTIVE_NOT_RECRUITINGB-Receptor Signaling in CardiomyopathyNCT01135849 · 2008-11-01
COMPLETEDCommon interventions
Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeksGENETIC1benmelstobart InjectionCOMBINATION_PRODUCT1PlaceboOTHER1RiluzoleDRUG1SamplesOTHER1TCC1727 tablet 120mgDRUG1TCC1727 tablet 160mgDRUG1TCC1727 tablet 90mgDRUG1
Leading sponsors
Trial status mix
RECRUITING3
ACTIVE_NOT_RECRUITING1
COMPLETED1
Phase mix
PHASE12
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.